- Molecular NameMitotane
- SynonymNA
- Weight320.046
- Drugbank_IDDB00648
- ACS_NO53-19-0
- Show 2D model
- LogP (experiment)6.372
- LogP (predicted, AB/LogP v2.0)6.36
- pkaN/A
- LogD (pH=7, predicted)6.36
- Solubility (experiment)0.0001 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-6.48
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)0.0
- No.of HBond Donors0
- No.of HBond Acceptors0
- No.of Rotatable Bonds3
- TPSA0.0
- StatusFDA approved
- AdministrationN/A
- PharmacologyA medication used in the treatment of the rare disease adrenocortical carcinoma.
- Absorption_value40.0
- Absorption (description)N/A
- Caco_2N/A
- BioavailabilityN/A
- Protein binding6.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic
- Half life18~159 days
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityThe main types of adverse reactions consist of the following. Gastrointestinal disturbances, which consist of anorexia, nausea or vomiting, and in some cases diarrhea, occur in about 80% of the patients. Central nervous system side effects occur in 40% of the patients. These consist primarily of depression as manifested by lethargy and somnolence (25%), and dizziness or vertigo (15%). Skin toxicity has been observed in about 15% of the cases. These skin changes consist primarily of transient skin rashes which do not seem to be dose related.
- LD50 (rat)N/A
- LD50 (mouse)N/A